165 related articles for article (PubMed ID: 23793608)
1. Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma.
Han Y; Zhang W; Liu Y
World J Surg; 2013 Oct; 37(10):2419-27. PubMed ID: 23793608
[TBL] [Abstract][Full Text] [Related]
2. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.
Guo S; Liu HD; Liu YF; Liu L; Sun Q; Cui XJ
Tumour Biol; 2015 Jan; 36(1):353-64. PubMed ID: 25262276
[TBL] [Abstract][Full Text] [Related]
3. BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma.
Li J; Yang Z; Huang S; Li D
Technol Cancer Res Treat; 2020; 19():1533033820971676. PubMed ID: 33234031
[TBL] [Abstract][Full Text] [Related]
4. [Expression of Survivin protein in extrahepatic cholangiocarcinoma and its relationship with the prognosis].
Qin XL; Xue HZ; Wang ZR; Liu HS; Zhou HB; Ma W
Zhonghua Wai Ke Za Zhi; 2009 Dec; 47(24):1852-6. PubMed ID: 20193400
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray.
Nitta T; Mitsuhashi T; Hatanaka Y; Miyamoto M; Oba K; Tsuchikawa T; Suzuki Y; Hatanaka KC; Hirano S; Matsuno Y
Br J Cancer; 2014 Sep; 111(7):1363-72. PubMed ID: 25077440
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma.
Liu YF; Zhao R; Guo S; Wang XQ; Lian PL; Chen YG; Xu KS
Ann Surg Oncol; 2011 Mar; 18(3):872-9. PubMed ID: 20848225
[TBL] [Abstract][Full Text] [Related]
7. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H
Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177
[TBL] [Abstract][Full Text] [Related]
8. DJ-1 is a useful biomarker for invasive extrahepatic cholangiocarcinoma.
Tabata Y; Nakanishi Y; Hatanaka KC; Hatanaka Y; Tsuchikawa T; Okamura K; Noji T; Shichinohe T; Matsuno Y; Hirano S
Hum Pathol; 2018 Jun; 76():28-36. PubMed ID: 29447925
[TBL] [Abstract][Full Text] [Related]
9. Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma.
Xu S; Huang S; Li D; Zou Q; Yuan Y; Yang Z
Anal Cell Pathol (Amst); 2020; 2020():9831646. PubMed ID: 32850288
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma.
Shimura T; Shibata M; Gonda K; Kofunato Y; Okada R; Ishigame T; Kimura T; Kenjo A; Marubashi S; Kono K; Takenoshita S
J Invest Surg; 2018 Dec; 31(6):475-482. PubMed ID: 28925763
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma.
Tsukagoshi M; Wada S; Yokobori T; Altan B; Ishii N; Watanabe A; Kubo N; Saito F; Araki K; Suzuki H; Hosouchi Y; Kuwano H
Cancer Sci; 2016 Feb; 107(2):116-22. PubMed ID: 26608587
[TBL] [Abstract][Full Text] [Related]
12. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.
Lee HJ; Chung JY; Hewitt SM; Yu E; Hong SM
Virchows Arch; 2012 Nov; 461(5):521-30. PubMed ID: 23052372
[TBL] [Abstract][Full Text] [Related]
13. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
14. Human G-protein gamma 7 in extrahepatic cholangiocarcinoma and its clinicopathological significance.
Wang M; Gong B; Li Y; Wang Y
Hematol Oncol Stem Cell Ther; 2010; 3(2):66-70. PubMed ID: 20543539
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer.
Song DH; Cho IK; Shin DW; Lee JC; Cho JY; Yoon YS; Hwang JH; Han HS; Kim J
Surg Today; 2021 Jun; 51(6):978-985. PubMed ID: 33387024
[TBL] [Abstract][Full Text] [Related]
16. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
17. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.
Aoki S; Mizuma M; Takahashi Y; Haji Y; Okada R; Abe T; Karasawa H; Tamai K; Okada T; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Katayose Y; Unno M
BMC Cancer; 2016 Nov; 16(1):854. PubMed ID: 27821106
[TBL] [Abstract][Full Text] [Related]
18. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells.
Liu Y; Sun J; Yang G; Liu Z; Guo S; Zhao R; Xu K; Wu X; Zhang Z
Mol Med Rep; 2015 Sep; 12(3):4713-4719. PubMed ID: 26081074
[TBL] [Abstract][Full Text] [Related]
20. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma.
Zhou L; He XD; Cui QC; Zhou WX; Qu Q; Zhou RL; Rui JA; Yu JC
Cancer Lett; 2008 Jun; 264(2):209-17. PubMed ID: 18334282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
